Here are the staff publications for November 2022.

Compiled by the Health Sciences Library (RMH, RWH, PMCC & Victorian Mental Health) 5th December 2022.

1. Ahn MJ, Mendoza MJL, Pavlakis N, Kato T, Soo RA, Kim DW, Liam CK, Hsia TC, Lee CK, Reungwetwattana T, Geater S, Chan OSH, Prasongsook N, Solomon BJ, Nguyen TTH, Kozuki T, Yang JC, Wu YL, Mok TSK, Tan DS, Yatabe Y. Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations. Clin Lung Cancer 2022;23:670-85.
2. Alhamdani Z, Ong S, Lawrentschuk N, Woon D. A Unique Urine Isolating Drape Technique for on Table Pyeloscopy Post Radical Cystectomy for a Suspected Upper Tract Lesion With an Obliterated Ureteric Orifice. Urology 2022;170:e6-e7.
3. Ali M, Mooi J, Lawrentschuk N, McKay RR, Hannan R, Lo SS, Hall WA, Siva S. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma. Eur Urol 2022;82:613-22.
4. Allard N, Miller A, Morgan M, Chakraborty S. Post-COVID-19 syndrome/condition or long COVID: Persistent illness after acute SARS CoV-2 infection. Aust J Gen Pract 2022;51:952-7.
5. Azad AA, Kostos L, Agarwal N. KIT as a therapeutic target in neuroendocrine prostate cancer. Cancer Cell 2022;40:1266-8.
6. Bae S, Brnabic A, Crowe P, Carey-Smith R, Andelkovic V, Singhal N, Stalley P, Yip D, Desai J. Managing patients with advanced soft tissue sarcoma: Evolving landscape from an Australian perspective. Asia Pac J Clin Oncol 2022;18:605-13.
7. Baldwin LA, Bartonicek N, Yang J, Wu SZ, Deng N, Roden DL, Chan CL, Al-Eryani G, Zanker DJ, Parker BS, Swarbrick A, Junankar S. DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response. Nat Commun 2022;13:6539.
8. Brandl A, Lundon D, Lorenzon L, Schrage Y, Caballero C, Holmberg CJ, Santrac N, Vasileva-Slaveva M, Montagna G, Sgarbura O, Sayyed R, Ben-Yaacov A, Herrera Kok JH, Suppan I, Mohan H, Kovacs T, D'Ugo D, Sandrucci S, Ceelen W, Academy ER. Standards in surgical training in advanced pelvic malignancy across Europe and beyond - A Snapshot analysis. Eur J Surg Oncol 2022;48:2338-45.
9. Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS, Thera PTI, the A, New Zealand U, Prostate Cancer Trials G. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol 2022;23:1389-97.
10. Chan JM, Clendenning M, Joseland S, Georgeson P, Mahmood K, Walker R, Como J, Joo JE, Preston S, Hutchinson RA, Pope BJ, Metz A, Beard C, Purvis R, Arnold J, Vijay V, Konycheva G, Atkinson N, Parry S, Jenkins MA, Macrae FA, Rosty C, Winship IM, Buchanan DD. Rare germline variants in the AXIN2 gene in families with colonic polyposis and colorectal cancer. Fam Cancer 2022;21:399-413.
11. Chazan G, Anton A, Wong S, Shapiro J, Weickhardt A, Azad A, Kwan EM, Spain L, Gunjur A, Torres J, Parente P, Parnis F, Goh J, Gibbs P, Tran B. Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis. Asia Pac J Clin Oncol 2022;18:642-9.
12. Chiong E, Murphy DG, Buchan NC, Chua MLK, Hakim L, Hamid AR, Hong SK, Horvath LG, Kanesvaran R, Khochikar M, Letran J, Lojanapiwat B, Malek R, Ng ACF, Vinh NT, Pang ST, Poon DMC, Ong TA, Saad M, Schubach K, Shiroki R, Turkeri L, Williams S, Wong A, Ye D, Group ACT, Davis ID. Managing advanced prostate cancer in the Asia Pacific region: "Real-world" application of Advanced Prostate Cancer Consensus Conference 2019 statements. Asia Pac J Clin Oncol 2022;18:686-95.
13. Choy KT, Lee DJ, Prabhakaran S, Warrier S, Heriot A, Kong JC. The complication profile of low Hartmann's in rectal cancer: a systematic review and meta-analysis. ANZ J Surg 2022;92:2829-39.
14. Costa P, De Jesus T, Torriani-Pasin C, Polese J. Functional capacity and walking speed reserve in individuals with chronic stroke: A cross-sectional study. Physiother Theory Pract 2022;38:2563-7.
15. Devlin MJ, Miller R, Laforets F, Kotantaki P, Garsed DW, Kristeleit R, Bowtell DD, McDermott J, Maniati E, Balkwill FR. The Tumor Microenvironment of Clear-Cell Ovarian Cancer. Cancer Immunol Res 2022;10:1326-39.
16. DeVries AA, Dennis J, Tyrer JP, Peng PC, Coetzee SG, Reyes AL, Plummer JT, Davis BD, Chen SS, Dezem FS, Aben KKH, Anton-Culver H, Antonenkova NN, Beckmann MW, Beeghly-Fadiel A, Berchuck A, Bogdanova NV, Bogdanova-Markov N, Brenton JD, Butzow R, Campbell I, Chang-Claude J, Chenevix-Trench G, Cook LS, DeFazio A, Doherty JA, Dork T, Eccles DM, Eliassen AH, Fasching PA, Fortner RT, Giles GG, Goode EL, Goodman MT, Gronwald J, Group OS, Group A, Hakansson N, Hildebrandt MAT, Huff C, Huntsman DG, Jensen A, Kar S, Karlan BY, Khusnutdinova EK, Kiemeney LA, Kjaer SK, Kupryjanczyk J, Labrie M, Lambrechts D, Le ND, Lubinski J, May T, Menon U, Milne RL, Modugno F, Monteiro AN, Moysich KB, Odunsi K, Olsson H, Pearce CL, Pejovic T, Ramus SJ, Riboli E, Riggan MJ, Romieu I, Sandler DP, Schildkraut JM, Setiawan VW, Sieh W, Song H, Sutphen R, Terry KL, Thompson PJ, Titus L, Tworoger SS, Van Nieuwenhuysen E, Edwards DV, Webb PM, Wentzensen N, Whittemore AS, Wolk A, Wu AH, Ziogas A, Freedman ML, Lawrenson K, Pharoah PDP, Easton DF, Gayther SA, Jones MR. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci. J Natl Cancer Inst 2022;114:1533-44.
17. Dillon R, Maycock S, Jackson A, Fox S, Freeman S, Craddock C, Thomas C, Homer E, Leahy J, Mamwell A, Potter N, Russell N, Wei A, Ommen HB, Hemmaway C, Knapper S, Billingham L. Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial. BMC Cancer 2022;22:1174.
18. Douglas A, Thursky K, Slavin M. New approaches to management of fever and neutropenia in high-risk patients. Curr Opin Infect Dis 2022;35:500-16.
19. Elliott J, Ahlawat S, Prince HM, Kennedy G, Wells J, Huang G, Collins J, Bardy P, Van Der Weyden C, Ritchie D, Khot A. Long-term outcomes for allogeneic bone marrow transplantation in Sezary syndrome and mycosis fungoides. Bone Marrow Transplant 2022;57:1724-6.
20. Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, Thompson J, Moon D, Sheehan-Dare G, Alghazo O, Agrawal S, Murphy D, Stricker P, Hope TA, Hofman MS. The PRIMARY Score: Using Intraprostatic (68)Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis. J Nucl Med 2022;63:1644-50.
21. Fernando D, Larach JT, Flood MP, Warrier SK, McCormick JJ, Heriot AG, Waters PS. Cytoreductive surgery and concomitant hyperthermic thoracoabdominal chemotherapy for pseudomyxoma peritonei with abdominal and pleural involvement. ANZ J Surg 2022;92:3072-4.
22. Francis PA. Role of Ovarian Suppression in Early Premenopausal Breast Cancer. Hematol Oncol Clin North Am 2023;37:79-88.
23. Garcia K, Gingras AC, Harvey KF, Tanas MR. TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities. Trends Cancer 2022;8:1033-45.
24. Geyer CE, Jr., Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmana J, Bergh J, Bliss J, Delaloge S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Johannsson O, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marme F, Martinez de Duenas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Spanic T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ, Olympi ACTSC, Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol 2022;33:1250-68.
25. Gillespie E, Faul C, Worth LJ. "Hands off hand hygiene training": Implementation of a COVID safe auditor training program. Am J Infect Control 2022;50:1271-3.
26. Glewis S, Alexander M, Lingaratnam S, Lee B, Campbell I, Krishnasamy M, M IJ, Fagery M, Harris S, Georgiou C, Underhill C, Warren M, Campbell R, Martin J, Tie J, Michael M. Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial. Acta Oncol 2022;61:1136-9.
27. Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33:1217-38.
28. Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J, This email address is being protected from spambots. You need JavaScript enabled to view it. EGCEa. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33:1217-38.
29. Hegi-Johnson F, Rudd SE, Wichmann C, Akhurst T, Roselt P, Trinh J, John T, Devereux L, Donnelly PS, Hicks R, Scott AM, Steinfort D, Fox S, Blyth B, Parakh S, Hanna GG, Callahan J, Burbury K, MacManus M. ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with (89)Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol. BMJ Open 2022;12:e056708.
30. Higgins MJ, Harrop S, Lade S, Prince HM, McCormack C, Campbell BA. Unifocal cutaneous blastic plasmacytoid dendritic cell neoplasm with a favorable response following high-dose radiotherapy alone. Leuk Lymphoma 2022;63:3004-7.
31. Ho GY, Kyran EL, Bedo J, Wakefield MJ, Ennis DP, Mirza HB, Vandenberg CJ, Lieschke E, Farrell A, Hadla A, Lim R, Dall G, Vince JE, Chua NK, Kondrashova O, Upstill-Goddard R, Bailey UM, Dowson S, Roxburgh P, Glasspool RM, Bryson G, Biankin AV, Cooke SL, Ratnayake G, McNally O, Traficante N, DeFazio A, Weroha SJ, Bowtell DD, McNeish IA, Papenfuss AT, Scott CL, Barker HE. Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin. Cancer Res 2022;82:4457-73.
32. Ho GY, Kyran EL, Bedo J, Wakefield MJ, Ennis DP, Mirza HB, Vandenberg CJ, Lieschke E, Farrell A, Hadla A, Lim R, Dall G, Vince JE, Chua NK, Kondrashova O, Upstill-Goddard R, Bailey UM, Dowson S, Roxburgh P, Glasspool RM, Bryson G, Biankin AV, Scottish Genomes P, Cooke SL, Ratnayake G, McNally O, Traficante N, Australian Ovarian Cancer S, DeFazio A, Weroha SJ, Bowtell DD, McNeish IA, Papenfuss AT, Scott CL, Barker HE. Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin. Cancer Res 2022;82:4457-73.
33. Hong AM, Lo H, Lawless A, Zhou D, Bae S, Phillips M, Maclean F, Desai J, Mar J, Lazarakis S, Pryor D, Thompson SR. The benefit for radiotherapy at specialised sarcoma centres: A systematic review and clinical practice guidelines from the Australia and New Zealand Sarcoma Association. Radiother Oncol 2022;177:158-62.
34. Hyatt A, Chung H, Aston R, Gough K, Krishnasamy M. Social return on investment economic evaluation of supportive care for lung cancer patients in acute care settings in Australia. BMC Health Serv Res 2022;22:1399.
35. Ishizawa T, McCulloch P, Stassen L, van den Bos J, Regimbeau JM, Dembinski J, Schneider-Koriath S, Boni L, Aoki T, Nishino H, Hasegawa K, Sekine Y, Chen-Yoshikawa T, Yeung T, Berber E, Kahramangil B, Bouvet M, Diana M, Kokudo N, Dip F, White K, Rosenthal RJ. Assessing the development status of intraoperative fluorescence imaging for anatomy visualisation, using the IDEAL framework. BMJ Surg Interv Health Technol 2022;4:e000156.
36. Itchins M, Ainsworth H, Alexander M, Dean S, Dharmaraj D, Pavlakis N, Clarke SJ, Brown C, Torres J, Saqib A, Ladwa R, O'Byrne K, Moore M, Yip PY, Solomon B, John T, Kao S, Mitchell P, Parakh S. A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases. Clin Lung Cancer 2022;23:702-8.
37. Jameson MB, Stevenson ARL, Ngan SY. TNT: Raising more questions than answers? Asia Pac J Clin Oncol 2022;18:489-92.
38. Kok DL, Dushyanthen S, Peters G, Sapkaroski D, Barrett M, Sim J, Eriksen JG. Screen-based digital learning methods in radiation oncology and medical education. Tech Innov Patient Support Radiat Oncol 2022;24:86-93.
39. Kok PS, Antill YC, Scott CL, Lee CK. The impact of single agent PD-1 or PD-L1 inhibition on advanced endometrial cancers: meta-analysis. ESMO Open 2022;7:100635.
40. Kuypers J, Simmance N, Quach H, Hastie K, Kiss N. Nutrition support use and clinical outcomes in patients with multiple myeloma undergoing autologous stem cell transplant. Support Care Cancer 2022;30:9341-50.
41. Lasocki A, Abdalla G, Chow G, Thust SC. Imaging features associated with H3 K27-altered and H3 G34-mutant gliomas: a narrative systematic review. Cancer Imaging 2022;22:63.
42. Lasocki A, Buckland ME, Drummond KJ, Wei H, Xie J, Christie M, Neal A, Gaillard F. Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas. Neuroradiology 2022;64:2295-305.
43. Leal JL, John T. Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options. Clin Lung Cancer 2022;23:643-58.
44. Lee PW, Marshall AC, Knott GJ, Kobelke S, Martelotto L, Cho E, McMillan PJ, Lee M, Bond CS, Fox AH. Paraspeckle subnuclear bodies depend on dynamic heterodimerisation of DBHS RNA-binding proteins via their structured domains. J Biol Chem 2022;298:102563.
45. Loi S, Karapetis CS, McCarthy N, Oakman C, Redfern A, White M, Khasraw M, Doval DC, Gore V, Alam M, Binko J, Lu DR, Kim S, Boyle F. Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India. Asia Pac J Clin Oncol 2022;18:560-9.
46. Lok SW, De Boer R, Baron-Hay S, Button P, Devitt B, Forster BC, Fox P, Harold M, Ketheeswaran S, Kichenadasse G, Kiely BE, Marx G, Nott L, Pellegrini L, Tafreshi A, Gibbs P. Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic breast cancer in Australia (PeRSIA). Int J Cancer 2023;152:267-75.
47. Loo S, Dillon R, Ivey A, Anstee NS, Othman J, Tiong IS, Potter N, Jovanovic J, Runglall M, Chong CC, Bajel A, Ritchie D, Gray K, Yeoh ZH, McBean M, Gilkes A, Thomas I, Johnson S, Russell NH, Wei AH. Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome. Blood 2022;140:2407-11.
48. Lourenco RA, Khoo T, Crothers A, Haas M, Montgomery R, Ball D, Bressel M, Siva S. Cost-Effectiveness of Single Versus Multifraction SABR for Pulmonary Oligometastases: The SAFRON II Trial. Int J Radiat Oncol Biol Phys 2022;114:968-76.
49. Mangiola S, Doyle MA, Papenfuss AT. Interfacing Seurat with the R tidy universe. Bioinformatics 2021;37:4100-7.
50. Martin JM, Richardson M, Siva S, Cardoso M, Handmer M, Sidhom M. Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy. Lancet Oncol 2022;23:e534-e43.
51. Mazieres J, Iadeluca L, Shaw AT, Solomon BJ, Bauer TM, de Marinis F, Felip E, Goto Y, Kim DW, Mok T, Reisman A, Thurm H, Polli AM, Liu G. Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. Lung Cancer 2022;174:146-56.
52. McDonald J, O'Brien J, Kostos L, Lawrentschuk N, Azad AA, Murphy D, Chen K. Systemic therapy in metastatic hormone-sensitive prostate cancer. Curr Opin Support Palliat Care 2022;16:234-9.
53. Meagher NS, Hamilton P, Milne K, Thornton S, Harris B, Weir A, Alsop J, Bisinoto C, Brenton JD, Brooks-Wilson A, Chiu DS, Cushing-Haugen KL, Fereday S, Garsed DW, Gayther SA, Gentry-Maharaj A, Gilks B, Jimenez-Linan M, Kennedy CJ, Le ND, Piskorz AM, Riggan MJ, Shah M, Singh N, Talhouk A, Widschwendter M, Bowtell DDL, Candido Dos Reis FJ, Cook LS, Fortner RT, García MJ, Harris HR, Huntsman DG, Karnezis AN, Köbel M, Menon U, Pharoah PDP, Doherty JA, Anglesio MS, Pike MC, Pearce CL, Friedlander ML, DeFazio A, Nelson BH, Ramus SJ. Profiling the immune landscape in mucinous ovarian carcinoma. Gynecol Oncol 2022;168:23-31.
54. Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank CU, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel JC, Ugurel S, Zimmer L, Banks P, Spain L, Soon JA, Enokida T, Tahara M, Kähler KC, Seggewiss-Bernhardt R, Harvey C, Long GV, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French LE, Knauss S, Heinzerling LM. Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis. Data Brief 2022;45:108649.
55. Murphy D, Herrmann K, Hofman M. Leading in Urology and Pioneering in Social Media Outreach: A Conversation Among Declan Murphy, Ken Herrmann, and Michael Hofman. J Nucl Med 2022;63:1783-5.
56. Nguyen D, Kleeman NJ, Yager Z, Parker AG, Shean MB, Jefferies W, Wilson-Evered E, Pucinischi CP, Pascoe MC. Identifying barriers and facilitators to implementing mindfulness-based programmes into schools: A mixed methods study. Appl Psychol Health Well Being 2022;14:1172-88.
57. Nguyen JK, Routledge D, van Der Weyden C, Blombery P, Angel CM, Johnson D, Goh MS, Lee A. VEXAS syndrome: A dermatological perspective. Australas J Dermatol 2022;63:488-92.
58. Nowatzke J, Guedeney P, Palaskas N, Lehmann L, Ederhy S, Zhu H, Cautela J, Francis S, Courand PY, Deswal A, Ewer SM, Aras M, Arangalage D, Ghafourian K, Fenioux C, Finke D, Peretto G, Zaha V, Itzhaki Ben Zadok O, Tajiri K, Akhter N, Levenson J, Baldassarre L, Power J, Huang S, Collet JP, Moslehi J, Salem JE, International ICImrc. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry. Eur J Cancer 2022;177:197-205.
59. Nüssing S, Sutton VR, Trapani JA, Parish IA. Beyond target cell death - Granzyme serine proteases in health and disease. Mol Aspects Med 2022;88:101152.
60. O'Brien JS, McVey A, Kelly BD, Chee J, Lawrentschuk N. Recent developments in the diagnosis and management of N1 penile cancer. Curr Opin Urol 2023;33:64-9.
61. O'Brien JS, McVey A, Kelly BD, Jenjitranant P, Buteau J, Hofman MS, Kasivisvanithan V, Eapen R, Moon D, Murphy DG, Lawrentschuk N. Prostate-specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer. BJU Int 2022;130 Suppl 3:8-10.
62. Othman B, Huang D, Rajkomar A, Pham T, Smart P, Warrier S. Robotic retroperitoneal lymph node dissection in colorectal cancer. ANZ J Surg 2022;92:3037-9.
63. Papa N, Perera M, Bensley JG, Evans M, Millar J, Frydenberg M, Murphy DG, Bolton D. A decade of declining prostatectomy margin positivity within a prostate cancer clinical quality registry. Urol Oncol 2022;40:537 e19- e24.
64. Phung MT, Webb PM, DeFazio A, Fereday S, Lee AW, Bowtell DDL, Fasching PA, Goode EL, Goodman MT, Karlan BY, Lester J, Matsuo K, Modugno F, Brenton JD, Van Gorp T, Pharoah PDP, Schildkraut JM, McLean K, Meza R, Mukherjee B, Richardson J, Grout B, Chase A, McKinnon Deurloo C, Terry KL, Hanley GE, Pike MC, Berchuck A, Ramus SJ, Pearce CL. Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery. Gynecol Oncol 2022;168:68-75.
65. Ptasznik G, Papa N, Kelly BD, Thompson J, Stricker P, Roberts MJ, Hofman MS, Buteau J, Murphy DG, Emmett L, Moon D. High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer. BJU Int 2022;130 Suppl 3:5-7.
66. Quah PS, Sutton V, Whitlock E, Figgett WA, Andrews DM, Fairfax KA, Mackay F. The effects of B-cell-activating factor on the population size, maturation and function of murine natural killer cells. Immunol Cell Biol 2022;100:761-76.
67. Ramsey I, Chan A, Charalambous A, Cheung YT, Darling HS, Eng L, Grech L, Hart NH, Kirk D, Mitchell SA, Poprawski D, Rammant E, Fitch MI, Chan RJ. Exercise counselling and referral in cancer care: an international scoping survey of health care practitioners' knowledge, practices, barriers, and facilitators. Support Care Cancer 2022;30:9379-91.
68. Rasheduzzaman M, Murugan AVM, Zhang X, Oliveira T, Dolcetti R, Kenny L, Johnson NW, Kolarich D, Punyadeera C. Head and neck cancer N-glycome traits are cell line and HPV status-dependent. Anal Bioanal Chem 2022;414:8401-11.
69. Ryan JT, Nakayama M, Gleeson I, Mannion L, Geso M, Kelly J, Ng SP, Hardcastle N. Functional brain imaging interventions for radiation therapy planning in patients with glioblastoma: a systematic review. Radiat Oncol 2022;17:178.
70. Ryckman JM, Thomas TV, Wang M, Wu X, Siva S, Spratt DE, Slotman B, Pal S, Chapin BF, Fitzal F, Soran A, Bex A, Louie AV, Lehrer EJ, Zaorsky NG. Local Treatment of the Primary Tumor for Patients With Metastatic Cancer (PRIME-TX): A Meta-Analysis. Int J Radiat Oncol Biol Phys 2022;114:919-35.
71. S MS, Langley DP, Cossins LR, Samudra AN, Quigley AF, Kapsa RMI, Tothill RW, Greene GW, Moulton SE. Rapid Point-of-Care Electrochemical Sensor for the Detection of Cancer Tn Antigen Carbohydrate in Whole Unprocessed Blood. ACS Sens 2022;7:3379-88.
72. Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jimenez-Ubieto A, Davis KL, Anjos C, Chu J, Zhang J, Lobetti Bodoni C, Thieblemont C, Fowler NH, Dickinson M, Martinez-Lopez J, Wang Y, Link BK. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv 2022;6:5835-43.
73. See D, Le B, Gorelik A, Eastman P. Symptom burden in malignant and non-malignant disease on admission to a palliative care unit. BMJ Support Palliat Care 2022;12:e792-e7.
74. Sheehan B, Guo C, Neeb A, Paschalis A, Sandhu S, de Bono JS. Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. Eur Urol Focus 2022;8:1157-68.
75. Sim BZ, Yong KY, Slavin MA, Yong MK. Risk factors and outcome of concurrent and sequential multiviral cytomegalovirus, Epstein-Barr virus, BK virus, adenovirus and other viral reactivations in transplantation. Curr Opin Infect Dis 2022;35:536-44.
76. Siva S, Ali M, Correa RJM, Muacevic A, Ponsky L, Ellis RJ, Lo SS, Onishi H, Swaminath A, McLaughlin M, Morgan SC, Cury FL, Teh BS, Mahadevan A, Kaplan ID, Chu W, Grubb W, Hannan R, Staehler M, Warner A, Louie AV. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol 2022;23:1508-16.
77. Siva S, Jones G, Bressel M, Shaw M, Chander S, Chu J, Plumridge N, Byrne K, Kothari G, Hardcastle N, Gaudreault M, Kron T, Wheeler G, MacManus M, Hanna GG, Ball DL, David S. Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for Oligometastases. Int J Radiat Oncol Biol Phys 2022;114:862-70.
78. Spicer JA, Huttunen KM, Jose J, Dimitrov I, Akhlaghi H, Sutton VR, Voskoboinik I, Trapani J. Small Molecule Inhibitors of Lymphocyte Perforin as Focused Immunosuppressants for Infection and Autoimmunity. J Med Chem 2022;65:14305-25.
79. Tedjaseputra A, Kuzich JA, Thiagarajah N, Teh TC, McClelland J, Rahman M, Brook R, Chua CC, Ong DM, Tan SY, Filshie R, Fong CY, Fedele P, Bajel A, Shortt J, Wei AH. Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic. Leuk Lymphoma 2022;63:2731-4.
80. Thijssen R, Tian L, Anderson MA, Flensburg C, Jarratt A, Garnham AL, Jabbari JS, Peng H, Lew TE, Teh CE, Gouil Q, Georgiou A, Tan T, Djajawi TM, Tam CS, Seymour JF, Blombery P, Gray DHD, Majewski IJ, Ritchie ME, Roberts AW, Huang DCS. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy. Blood 2022;140:2127-41.
81. Tower H, Dall G, Davey A, Stewart M, Lanteri P, Ruppert M, Lambouras M, Nasir I, Yeow S, Darcy PK, Ingman WV, Parker B, Haynes NM, Britt KL. Estrogen-induced immune changes within the normal mammary gland. Sci Rep 2022;12:18986.
82. Tudini E, Andrews J, Lawrence DM, King-Smith SL, Baker N, Baxter L, Beilby J, Bennetts B, Beshay V, Black M, Boughtwood TF, Brion K, Cheong PL, Christie M, Christodoulou J, Chong B, Cox K, Davis MR, Dejong L, Dinger ME, Doig KD, Douglas E, Dubowsky A, Ellul M, Fellowes A, Fisk K, Fortuno C, Friend K, Gallagher RL, Gao S, Hackett E, Hadler J, Hipwell M, Ho G, Hollway G, Hooper AJ, Kassahn KS, Krishnaraj R, Lau C, Le H, San Leong H, Lundie B, Lunke S, Marty A, McPhillips M, Nguyen LT, Nones K, Palmer K, Pearson JV, Quinn MCJ, Rawlings LH, Sadedin S, Sanchez L, Schreiber AW, Sigalas E, Simsek A, Soubrier J, Stark Z, Thompson BA, U J, Vakulin CG, Wells AV, Wise CA, Woods R, Ziolkowski A, Brion MJ, Scott HS, Thorne NP, Spurdle AB. Shariant platform: Enabling evidence sharing across Australian clinical genetic-testing laboratories to support variant interpretation. Am J Hum Genet 2022;109:1960-73.
83. Viljoen B, Hofman MS, Chambers SK, Dunn J, Dhillon HM, Davis ID, Ralph N. Experiences of participants in a clinical trial of a novel radioactive treatment for advanced prostate cancer: A nested, qualitative longitudinal study. PLoS One 2022;17:e0276063.
84. Walker H, Shanthikumar S, Cole T, Neeland M, Hanna D, Haeusler GM. Novel approaches to the prediction and diagnosis of pulmonary complications in the paediatric haematopoietic stem cell transplant patient. Curr Opin Infect Dis 2022;35:493-9.
85. Wang J, Prabhakaran S, Larach T, Warrier SK, Bednarski BK, Ngan SY, Leong T, Rodriguez-Bigas M, Peacock O, Chang G, Heriot AG, Kong JC. Treatment strategies for locally recurrent rectal cancer. Eur J Surg Oncol 2022;48:2292-8.
86. Wierda WG, Kipps TJ, Al-Sawaf O, Chyla B, Biondo JML, Mun Y, Jiang Y, Seymour JF. Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. Leuk Lymphoma 2022;63:2765-84.
87. Wolyniec K, Sharp J, Fisher K, Tothill RW, Bowtell D, Mileshkin L, Schofield P. Psychological distress, understanding of cancer and illness uncertainty in patients with Cancer of Unknown Primary. Psychooncology 2022;31:1869-76.
88. Wong AK, Grobler A, Le B. ENhANCE trial protocol: A multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer. Contemp Clin Trials Commun 2022;30:101036.
89. Wong V, de Boer R, Baron-Hay S, Blum R, Boyle F, Chua S, Clarke K, Cuff K, Green M, Lim E, Mok K, Nott L, Nottage M, Tafreshi A, Tsoi D, Uccellini A, Hong W, Gibbs P, Lok SW. Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer. Clin Breast Cancer 2022;22:792-800.
90. Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia 2022;36:2939-46.
91. Zomerdijk N, Panozzo S, Mileshkin L, Yoong J, Nowak AK, Stockler MR, Philip J. Palliative care facilitates the preparedness of caregivers for thoracic cancer patients. Eur J Cancer Care (Engl) 2022;31:e13716.